Fusion Pharmaceuticals Inc. /
RadioMedix
Fusion Pharmaceuticals takes on RadioMedix assets for FPI-2265
- Price
- $1.5m
- Stage
- Closed
What happened
Fusion Pharmaceuticals Inc. exercised its option to acquire certain RadioMedix, Inc. assets related to the TATCIST Study, a Phase 2 clinical trial evaluating 225-actinium PSMA I&T. The acquisition closed on Feb. 10, 2023.
Fusion paid a $1.5 million exercise fee. Additional payments may include clinical and regulatory milestones, royalties and net sales milestones.
The source
Everything on this page comes from the source below.
Fusion Pharmaceuticals takes on RadioMedix assets for FPI-2265
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly